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The second messenger molecule cAMP links extracellular signals to intracellular
responses. The main cellular cAMP effector is the compartmentalized protein kinase
A (PKA). Upon receptor initiated cAMP-mobilization, PKA regulatory subunits (R) bind
cAMP thereby triggering dissociation and activation of bound PKA catalytic subunits
(PKAc). Mutations in PKAc or RIa subunits manipulate PKA dynamics and activities
which contribute to specific disease patterns. Mutations activating cAMP/PKA signaling
contribute to carcinogenesis or hormone excess, while inactivating mutations cause
hormone deficiency or resistance. Here we extended the application spectrum of a
Protein-fragment Complementation Assay based on the Renilla Luciferase to determine
binary protein:protein interactions (PPIs) of the PKA network. We compared time- and
dose-dependent influences of cAMP-elevation on mutually exclusive PPIs of PKAc with
the phosphotransferase inhibiting RIIb and RIa subunits and the protein kinase inhibitor
peptide (PKI). We analyzed PKA dynamics following integration of patient mutations
into PKAc and RIa. We observed that oncogenic modifications of PKAc(L206R) and
RIa(1184-236) as well as rare disease mutations in RIa(R368X) affect complex formation
of PKA and its responsiveness to cAMP elevation. With the cell-based PKA PPI reporter
platform we precisely quantified the mechanistic details how inhibitory PKA interactions
and defined patient mutations contribute to PKA functions.
Keywords: molecular interactions, patient mutations, cAMP-dependent protein kinase A, protein-fragment
complementation assay, GPCR, Carney complex, Acrodysostosis
Introduction
Small molecules represent the vast majority of cellular components. They are either substrates or
products of numerous biochemical reactions. By acting as hormones or ligands, small molecules
control protein functions, and molecular interactions which affect signal transmission. Molecular
interactions of secondmessenger molecules with distinct proteins alter protein:protein interactions
(PPIs) and signal propagation (Clapham, 2007; Scott and Pawson, 2009; Taylor et al., 2012; Li et al.,
2013). The secondmessenger concept explains the dynamic wiring of membrane receptor pathways
to a vast array of intracellular PPIs. One prominent example is the canonical second messenger
molecule cyclic AMP (cAMP). It is an evolutionary conserved transmitter of membrane receptor
originating input signals. A large number of G protein-coupled receptor (GPCR) cascade utilizes
cAMP as intracellular second messenger (Neves et al., 2002; Pierce et al., 2002; Lefkowitz, 2007;
O’Hayre et al., 2014). cAMPmolecules dynamically bind to and regulate activities of its key effector
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kinase, the cAMP-dependent protein kinase A (PKA). The
mechanistic details of cAMP-PKA activation is a textbook
paradigm for allostery and small molecule:protein interactions
(Taylor et al., 2012; Zhang et al., 2012). In its inactive
state the PKA holoenzyme consists of a PKA regulatory
subunit homodimer (R; type Ia, Ib, IIa, IIb) which inhibits
the phosphotransferase activity of two PKA catalytic subunits
(PKAc) through binding. Upon selective GPCR activation
cAMP production through adenylyl cyclase (AC) activities is
initiated; on the contrary, phosphodiesterase (PDE) control
cAMP degradation (Dessauer, 2009; Houslay, 2010). cAMP
binding to spatially compartmentalized type I (RI2:PKAc2) or
type II (RII2:PKAc2) PKA holoenzymes causes a conformational
change, hence dissociation, and activation of phosphotransferase
activities of PKAc. As a consequence PKAc phosphorylates
compartmentalized substrates which affects enzyme activities,
PPI, localization, or protein abundance (Scott and Pawson, 2009;
Lignitto et al., 2011, 2013; Taylor et al., 2012; Bachmann et al.,
2013; Scott et al., 2013; Filteau et al., 2015). To guarantee
substrate specificity PKA R subunits bind A kinase-anchoring
proteins (AKAPs) which organize the subcellular targeting of
PKA activities (Wong and Scott, 2004; Skroblin et al., 2010;
Scott et al., 2013). To desensitize PKA phosphotransferase
activities nuclear PKAc subunits are specifically inhibited
through binding to the protein kinase inhibitor peptide (PKI)
(Walsh et al., 1971; Scott et al., 1985; Dalton and Dewey, 2006).
Deregulation of cAMP/PKA functions contribute to different
diseases. Inactivating PRKAR1A gene (RIa) and activating
PRKACA gene (PKAc) mutations/fusions provoke deregulated
PKAc activities. As examples, mutations in RIa and PKAc
account for the generation of endocrine tumors, cortisol-
producing adenomas, and chimeric fusions with PKAc have
been linked to the manifestation of hepatocellular carcinoma
(Groussin et al., 2002; Meoli et al., 2008; Stratakis, 2013;
Beuschlein et al., 2014; Calebiro et al., 2014; Cao et al., 2014;
Di Dalmazi et al., 2014; Espiard et al., 2014; Goh et al., 2014;
Honeyman et al., 2014; Sato et al., 2014; Cheung et al., 2015;
Zilbermint and Stratakis, 2015). However, specific PRKAR1A
gene (RIa) mutations impair cAMP-dependent PKA activation
and cause hormone resistance as observed in the rare disease
Acrodysostosis (a form of skeletal dysplasia) (Linglart et al.,
2011; Assié, 2012; Silve et al., 2012). Here we tested the
impact of functionally different PKA mutations on mutually
exclusive molecular protein interactions using an extended
PPI reporter platform based on the Renilla luciferase protein-
fragment complementation assay (Rluc PCA) (Stefan et al., 2007;
Röck et al., 2015). We show that the presented Rluc PCA
platform—which is based on binary PKA network interactions—
can be applied to analyze the consequences of patient mutations
and upstream receptor activities on defined PKA PPIs directly in
living cells.
Materials and Methods
Cell Culture and Antibodies
HEK293 and U2OS cells were grown in DMEM supplemented
with 10% FBS. Transient transfections were performed with
Transfectin reagent (Biorad). Cells were treated with Forskolin
(Biaffin) or Isoproterenol (Sigma) with indicated concentrations
and for the indicated time frames. As primary antibody we used
mouse anti-PKAc (BD Bioscience, #610981).
Constructs
The Rluc PCA based hybrid proteins RIIb-F[1] and PKAc-F[2]
have been designed as previously described (Stefan et al., 2007).
Rluc PCA fusions with PKI and RIa have been generated using
an analogous cloning approach. Following PCR amplification of
the of the human RIa (alpha) gene (protein accession number:
NP_002725.1) and PKI alpha gene (protein accession number:
AAA72716; addgene plasmid # 45066) (Day et al., 1989) we
fused them C-terminally with either -F[1] or -F[2] of the Rluc
PCA. PKA subunits and PKI were subcloned into the 5′ end the
10aa linker (GGGGS)2 and the Rluc PCA fragments (pcDNA3.1
backbone vector). Site directedmutagenesis have been performed
to generate the PKAc amino acid (aa) mutations G187V and
L206R in the PRKACA gene and the RIa aa mutations R368X (X
stands for the stop codon of the patient mutation; we generated
the corresponding RIa truncation) in the PRKAR1A gene. In
addition we deleted the corresponding nucleotide sequence from
the aa 184–236 in the PRKAR1A gene.
Renilla Luciferase PCA of Detached Cells
HEK293 cells were grown in DMEM supplemented with 10%
FBS. We transiently overexpressed indicated versions of the Rluc
PCA based reporter constructs in 24 or 12 well-plate formats.
In case of the HEK293 cells we exchanged growth medium
and resuspended cells in PBS 24 or 48 h post-transfection. Cell
suspensions were transferred to 96-well plates and subjected
to luminescence analysis using the LMax™-II-384 luminometer
(Molecular Devices). Rluc luminescence signals were integrated
for 10 s.
Renilla Luciferase PCA of Attached Cells
We seeded U2OS cells into white-walled 96 well-plates with
transparent bottom. We transiently overexpressed indicated
versions of the Rluc PCA based reporter constructs. 24 or 48 h
post-transfection we exchanged growth medium with PBS. We
performed luminescence analyses of attached U2OS cells at room
temperature using the LMax™-II-384 luminometer (Molecular
Devices). Time dependent changes of the Rluc luminescence
signals were integrated in 3-s intervals following addition of
the Rluc substrate benzyl-coelenterazine (5µM; Nanolight) with
or without Isoproterenol (final concentration 10µM) (Stefan
et al., 2007). Following determination of the Rluc PCA signals we
normalized the resulting signals on the control experiment (data
points without Isoproterenol treatment).
Results
The purpose of our study was to extend the application spectrum
of a PPI reporter platform (Rluc PCA) to quantify mutually
exclusive PKA interactions directly in living cells. It is the
simplicity and sensitivity of the genetically encoded Rluc PCA
which enables different kinds of perturbation studies to unveil
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mechanistic details of PKA dynamics. The Rluc PCA facilitates
the precise quantification of cellular PPI in an appropriate
in vivo setting (Röck et al., 2015). In Figure 1 we illustrate
the Rluc PCA design principle to analyze binary PPI of PKAc
subunits. PPIs of R subunits and PKI with PKAc trigger
folding and complementation of appended PCA-fragments.
Following addition of the Rluc substrate benzyl-coelenterazine
Rluc PCA emitted bioluminescence signals reflect quantifiable
cellular PPI. Elevations of cAMP levels and defined patient
mutations in RIa or PKAc affect PPI between the kinase
inhibitory proteins (R/PKI) and PKAcwhich is indicated through
alterations of bioluminescence signals. For the cloning of the
PPI reporter constructs we fused the carboxy terminus of the
PKA subunits (PKAc, RIIb, RIa) and PKI to complementary
fragments of the Rluc PCA (either -F[1] or -F[2]). In all
cases the bait/prey proteins and the Rluc PCA fragments are
separated by an interjacent 10 amino acid (aa) linker with
the sequence (GGGGS)2. It is a standard linker we previously
showed to function using the dynamic RIIb:PKAc Rluc PCA
reporter (Stefan et al., 2007). We started with analyzes of time
and dose dependent effects of distinct cAMP elevating agents
on binary PKA interactions before we initiated investigations of
the correlation of cAMP elevation, PPI and patient mutations.
In our first tests we transiently over-expressed indicated Rluc
PCA pairs in HEK293 cells. We detected significant Rluc PCA
originating bioluminescence signals of existing PPI between
RIIb:RIIb, RIIb:PKAc, RIa:PKAc, and PKI:PKAc. No significant
bioluminescence signals with R subunit:PKI combinations were
detectable (Figure 2A). These data confirm the specificity of
the assay and the suitability to analyze PKAc complexes with
differentially localized phosphotransferase inhibitors. PKA R
subunits sense and bind cAMP. We tested different modes of
cAMP elevation. We used the general cAMP elevating agent
Forskolin to maximally activate AC mediated cAMP production.
In addition, we activated a prototypical GPCR which is coupled
to cAMP production, the beta-2 adrenergic receptor (β2AR),
respectively. In this context it needs to be considered that
distinct mechanism have been described how β2AR switch
their G protein coupling from stimulatory G proteins to
inhibitory ones (Baillie et al., 2003). We used HEK293 cells
stably expressing β2AR. Activation of different βAR subtypes
are related to proliferation, cardiac function, and memory and
learning (Daaka et al., 1997; Wong and Scott, 2004; Zhang et al.,
2005; Thaker et al., 2006; Lefkowitz, 2007). As predicted, we
observed that both Forskolin exposure and the activation of β2AR
(with Isoproterenol) triggered R:PKAc complex dissociation. We
observed no major changes of PPI between PKI:PKAc and RIIb
homodimers following 15min of cAMP elevation (Figure 2B).
These results indicate that discrete GPCR/cAMP activation
induces dissociation of heterodimeric RIa:PKAc and RIIb:PKAc
complexes which underlines the suitability of Rluc PCA to
characterize transient and small molecule regulated PPI in vivo.
In order to evaluate dose dependent changes of type I and
type II PKA dynamics we treated HEK293-β2AR cells with
increasing concentrations of the non-selective beta adrenergic
agonist Isoproterenol. We observed that similar half maximal
effective concentrations of Isoproterenol induce PKA type I
FIGURE 1 | Rluc PCA design principle. The PKA subunits PKAc, RIa, and
RIIb have been C-terminally tagged with Rluc PCA fragments (-F[1], -F[2]).
PPIs trigger folding and complementation of appended PCA-fragments. The
emitted bioluminescence signal is a quantitative description of cellular PPIs.
Elevations of cAMP levels and integration of distinct patient mutations in RIa
and PKAc affect protein complex formation. Following addition of the Rluc
substrate benzyl-coelenterazine Rluc PCA emitted bioluminescence signals
reflect quantifiable PPI.
and type II activation in the used stable HEK293 cell line
(Figure 3A). As predicted, we observed no major impact of
β2AR-mediated cAMP elevation on RIIb homodimers and
the PKI:PKAc complex. Next, we wanted to track time
dependent changes of the studied PPIs. We switched to the
well-attached human osteosarcoma cell line U2OS. We set
out to monitor GPCR mediated changes of PPI in the first
4min of agonist exposure of attached U2OS cells expressing
endogenous β2AR directly in the 96-multiwell plate (Stefan
et al., 2007). Following transient overexpression of the four Rluc
PCA pairs (RIa:PKAc, RIIb:PKAc, RIIb:RIIb, PKI:PKAc) and
full length Rluc we observed that Isoproterenol immediately
induced the dissociation of heterodimeric type I and type II
PKA complexes with similar kinetics. Again, β2AR activation
for 4min has no major effect on the RIIb dimer and on
PKAc:PKI interactions (Figure 3B). The results from the real-
time measurements of PKA kinetics using whole cell populations
underline the suitability of the Rluc PCA to compare subtype-
receptor controlled PPI dynamics in distinct cell settings.
Next, we analyzed different kind of patient mutations of
PKA subunits and their impact on binary PKA network
interactions. We selected patient mutations of PKAc and
RIa which contribute to disease etiology and progression
(Carney et al., 1985; Horvath et al., 2010; Stratakis, 2013;
Beuschlein et al., 2014; Calebiro et al., 2014; Cao et al., 2014;
Di Dalmazi et al., 2014; Espiard et al., 2014; Goh et al., 2014;
Honeyman et al., 2014; Salpea and Stratakis, 2014; Sato et al.,
2014; Cheung et al., 2015; Zilbermint and Stratakis, 2015). We
started with analyses of PKAc mutations and their effect on
compartmentalized PPI of PKAc with R subunits (type I and II)
and PKI (Figure 4A). In addition we investigated the impact of
cAMP alterations on wild type and mutant PKA complexes. We
introduced two patient mutations into the PKAc-F[2] Rluc PCA
constructs. It has been described that the PKAc mutation G187V
diminished, whereas the hotspot mutation L206R of PKAc in
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FIGURE 2 | Impact of receptor activities and kinase mutations on
PPIs of PKA in human cell lines. (A) Co-transfection of HEK293 cells
with indicated Rluc PCA pairs followed by Rluc PCA analyses have been
performed. The amount of PKI hybrid constructs have been bisected for
cell transfections (representative of n = 5; ±SD from triplicates). (B)
Indicated combinations of Rluc PCA tagged components of the binary
PKA network have been subjected to Rluc PCA measurements. The
effect of Forskolin (50µM; 15min) and Isoproterenol (10µM; 15min) on
complex formation has been determined (average from at least n = 3
independent experiments; ±SEM). Basal PPIs of RIIb:RIIb, RIIb:PKAc,
RIa:PKAc, and PKI:PKAc have been set to 100%. The percentage
change of PPI is shown.
FIGURE 3 | Time and dose dependent impact of β2AR activities on
PPIs. (A) HEK293-β2AR cells transiently expressing indicated Rluc PCA pairs
have been exposed to dose-dependent Isoproterenol treatments (15min).
PPIs have been determined using the Rluc PCA as read out (representative
experiment from n = 3; ±SD from triplicates). PPIs of RIIb:RIIb, RIIb:PKAc,
RIa:PKAc, and PKI:PKAc upon 1 pM Isoproterenol exposure have been set
to 100%. (B) U2OS cells transiently expressing indicated Rluc PCA pairs
have been exposed to time-dependent Isoproterenol treatments (10µM).
Time dependent changes of the Rluc luminescence signals were integrated
for 3 s intervals following addition of the Rluc substrate benzyl-coelenterazine
(5µM) with or without Isoproterenol. Following determination of Rluc PCA
signals we normalized the data points on the experiments with the full length
Rluc (±Isoproterenol) and on the control experiment (without Isoproterenol).
Shown is a representative experiment of n = 3; ±SEM.
adrenal Cushing’s syndrome promoted PKAc activity (Soberg
et al., 2012; Cao et al., 2014; Di Dalmazi et al., 2014; Sato et al.,
2014). Following co-expression of PCA pairs in HEK293 cells we
observed a significant reduction of complex formation of PKAc
mutants with all three PKA-inhibitory proteins. To our surprise
also the interaction with PKI was significantly reduced. cAMP
binding to the heterodimeric wild type PKA reporter (RIa:PKAc,
RIIb:PKAc) caused complex dissociation (Stefan et al., 2007,
2011; Bachmann et al., 2013). Only in the case of RIIb:PKAc-
G187V the remaining PPI was still responsive to general cAMP
elevation using Forskolin (Figure 4B). The expression level of
mutated PKAc-F[2] was slightly reduced (Figure 4C). These
data underline that the patient mutation PKAc-L206R and the
mutant PKAc-G187V significantly reduce complex formation
with RIa, RIIb, and PKI. However, we show that RIIb has still the
potential to bind to the catalytic inactive PKAc-G187V mutant.
No remaining PPIs of inhibitory R/PKI proteins with the critical
PKAc-L206R mutant were detected.
Following analyses of PKAc patient mutations we tested the
consequence of mutating RIa on complex formation with PKAc
(Figure 5A). In the RIa R subunit a variety of mutations have
been found which lead to distinct human diseases (Figure 5A)
(Horvath et al., 2010). We decided to test a patient mutation
which causes the expression of a RIa protein lacking the aa
sequence encoded by exon 6 (R1a 1184-236) which contribute
to the multiple neoplasia and lentiginosis syndrome Carney
complex (Groussin et al., 2002; Meoli et al., 2008). It is a disease
described as “the complex of myxomas, spotty skin pigmentation
and endocrine over activity” (Carney et al., 1985; Veugelers et al.,
2004; Horvath et al., 2010; Salpea and Stratakis, 2014). In case of
the Carney complex a collection of RIa mutations lead to PKA
activation. As second mutation we introduced one stop codon
at the position R368X in RIa which results in a truncation of
the last 14 amino acids of the RIa protein. This heterozygous de
novomutation has been identified in patients with Acrodysostosis
(a rare form of skeletal dysplasia) which is caused through a
resistance to several hormones (Linglart et al., 2011). In case of
Acrodysostosis RIa mutations lead to PKA inactivation.
To quantitatively evaluate the impact of these two patient
mutations on PPI we transfected the same DNA amount of
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FIGURE 4 | Impact of PKAc mutations and cAMP elevation on
PPIs emanating from PKAc. (A) cAMP elevation leads to PKA
activation: cAMP binds to R subunits and triggers dissociation of active
PKAc subunits which phosphorylate substrates in cytoplasm and
nucleus. PKI inactivates nuclear PKI complexes. PKAc mutations
deregulate the binary PKA network. (B) Following site directed
mutagenesis of PKAc-F[2], combinations of wild type and mutant Rluc
PCA tagged PKA subunits have been subjected to Rluc PCA
measurements. The effect of forskolin (50µM; 10min) on PKA complex
formation has been determined (n = 4 independent experiments, ±SEM).
(C) Immunoblotting shows expression levels of endogenous PKAc and
F[2]-tagged PKAc variants.
FIGURE 5 | Impact of RIa mutations and cAMP elevation on PKA
type I complexes. (A) Ligand-mediated activation of GPCR pathways
linked to cAMP production lead to activation of PKA holoenzymes.
cAMP binds to RIa subunits and triggers dissociation of active PKAc
subunits which phosphorylate substrates in cytoplasm and nucleus. RIa
mutations deregulate RIa:PKAc dynamics. (B) Following indicated
modifications of RIa-F[1] sequences, combinations of wild type and
mutant Rluc PCA tagged PKA subunits have been subjected to Rluc
PCA measurements. The effect of isoproterenol (1µM, 10min; 48 h
transient PCA reporter expression) on PKA complex formation has been
determined (at least n = 3 independent experiments, ±SEM). (C)
Analyses of Rluc PCA based homodimer formations of wild type and
mutated RIa have been performed (at least n = 3 independent
experiments, ±SEM).
indicated Rluc PCA constructs into HEK293 cells. We observed
that the R1a 1184-236 deletion in RIa-F[1] reduced basal
PPI with PKAc-F[2] to less than 50% (Figure 5B). No major
changes of R subunit dimerization of R1a 1184-236:RIa was
detectable (Figure 5C). Upon cAMP elevation with Isoproterenol
the remaining PKA complex can be activated to a similar extend
as the wild type PKA type I complex. In parallel we analyzed
the truncated RIa protein simulating the stop codon at position
R368 of RIa (=14aa truncation). First, we observed elevated levels
of inactive RIa:PKAc complexes. Second, upon cAMP elevation
with Isoproterenol we recorded less PKA dynamics (Figure 5B).
No major changes of R subunit dimerization of RIa-R368X:RIa
was detectable (Figure 5C). Apparently the RIa-R368X mutated
PKA type I complex is less responsive to cAMP elevations.
The R368X mutation impairs the cAMP-dependent dissociation
of RIa from PKAc. These data underline that specific patient
mutations in RIa have different consequences on both the PKA
holoenzyme complex formation and on cAMP-induced PKA
activation.
Overall our data indicate that the presented Rluc PCA PKA
reporter platform is suitable to quantify dynamic and mutually
exclusive protein complex assembly and disassembly of the
binary PKA network, which is controlled through oscillations
of cAMP levels. In addition, we clearly demonstrate with this
proof of concept study that observed PPI dynamics of wild type
and mutated PKA complexes support findings and hypotheses of
disease relevant PKA associations.
Discussion
The ability to precisely record PPI dynamics of the binary
PKA network is central for understanding compartmentalized
cAMP signal transmission. We present a highly sensitive and
easy applicable reporter platform to systematically quantify,
map, and manipulate PKA protein complex formation in
real time. We show that second messenger initiated changes
of PKA reflect connections to upstream located receptor
pathways. The implementation of the PPI reporter allows
Frontiers in Pharmacology | www.frontiersin.org 5 August 2015 | Volume 6 | Article 170
Röck et al. Mutations affect compartmentalized PKA interactions
for more accurate and quantitative specification of receptor-
effector relationships directly in the preferred cell type. In
light of disease relevant PKAc variations (mutations, fusions,
decontrolled upstream pathways) application of the PKA Rluc
PCA platform offers the possibility to systematically test different
means of kinase perturbations using the available biosensor
toolbox. We quantified mutually exclusive PKAc interactions
which account for different spatially controlled cell functions.
We showed that the PPI reporter implementation simplified the
determination of consequences of PPI relevant patientmutations.
Such comparative in vivo analyses will facilitate the decision
how to interfere with deregulated PKA functions. We showed
that two PKAc mutations display differences in the binary
PPI pattern. We revealed that cAMP-sensing R subunits and
PKI form no PPIs with PKAc-L206R, a hotspot mutation of
PKAc in adrenal Cushing’s syndrome which promotes PKAc
activity (Cao et al., 2014; Di Dalmazi et al., 2014). First, this
implements that PKAc-L206R cannot be compartmentalized
through R/PKI and indirect AKAP interactions. Second, PKAc-
L206R operates independently of cAMP. Therefore, alternative
means need to be prosecuted to reduce the deregulated
phosphotransferase activity. Besides inhibitory small molecules
we believe that targeting the stability of PKAc-L206R is one
alternative.
We also tested two patient mutations of RIa which are
related to two different diseases showing opposite effects on PKA
activity. We demonstrated that the Carney complex relevant
R1a-1184-236 mutation had a major impact on PKA complex
formationwhen compared to the wild type PKAholoenzyme type
I. Our data showed that R1a-1184-236 has less affinity for PKAc.
We assume that the reduced affinity for PKAc contributes to
disease relevant elevations of PKAc phosphotranferase activities.
The second mutation RIa-R368X (=14aa truncation) caused
a defect in PKA activation. The mutation introduces a stop
codon and shortens the cAMP binding domain B. The resulting
deletion of 14 aa at the C terminus reduced the cooperative
binding of cAMP first to binding domain B and then to binding
domain A, which is a prerequisite for PKAc dissociation and
activation (Kim et al., 2007; Bertherat et al., 2009; Linglart et al.,
2011; Taylor et al., 2012). We showed that this truncation is
sufficient to elevate basal RIa-1-368:PKAc complexes. Primarily
this complex was less responsive to GPCR/cAMP mediated PKA
activation what correlates with the findings of Linglart and
colleagues (Linglart et al., 2011; Silve et al., 2012). Interestingly,
we detectedmarginal cAMP-dependent activation of the mutated
PKA complex. This underscores the suitability of the PKA
Rluc PCA reporter to detect even modest changes of PPIs in
response to second messenger elevations. Overall we underline
with this study that the Rluc PCA is a versatile reporter
system to map transient and small molecule controlled PPI.
Besides linking membrane receptor pathways to alterations of
molecular interactions, the consequence of patient mutations
on PPI can be tested with a simple protocol and in parallel
fashion. The implementation of this PPI reporter platform will
unveil consequences of distinct patient mutations on binary PKA
network dynamics. We envision that the mutation approach will
disclose hot spots in these critically regulated kinase complexes
which become pharmaceutical targets to target both PPI and/or
cAMP sensing. This will help to gain novel insights into
mechanism of PKA activation which will be relevant for the
diagnosis and for identifying treatments of kinase involved
diseases.
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